Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications-Reference-Cited by-同舟云学术

Actiated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications

Published:2002-04 Issue:3 Volume:13 Page:187-192
ISSN:0957-5235
Container-title:Blood Coagulation & Fibrinolysis
language:en
Short-container-title:Blood Coagulation & Fibrinolysis

Author:

Zangari M.,Saghafifar F.,Anaissie E.,Badros A.,Desikan R.,Fassas A.,Mehta P.,Morris C.,Toor A.,Whitfield D.,Siegel E.,Barlogie B.,Fink L.,Tricot G.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology,General Medicine

Reference19 articles.

1. Anticoagulant protein C pathway defective in majority of thrombophilic patients [see comments]

2. Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism

3. Deep-Vein Thrombosis and the Incidence of Subsequent Symptomatic Cancer

4. Prognosis of Cancers Associated with Venous Thromboembolism

5. Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DVT as the Initial Presentation of Multiple Myeloma: A Rare Case Report and Literature Review;Cureus;2023-07-28

2. Monoclonal Gammopathy of Thrombotic Significance;Cancers;2023-01-12

3. Enhanced thrombin generation detected with ST-Genesia analyzer in patients with newly diagnosed multiple myeloma;Journal of Thrombosis and Thrombolysis;2023-01-11

4. Mechanisms Contributing to Acquired Activated Protein C Resistance in Patients Treated with Thalidomide: A Molecular Dynamics Study;Cardiovascular & Hematological Disorders-Drug Targets;2022-12

5. Risk Factors and Risk Stratification of Thromboembolic Risk in Patients with Multiple Myeloma;Hemato;2022-08-29